Cryoport reported a 16% year-over-year revenue increase to $47.8 million in Q1 2026, driven by strong growth in commercial cell and gene therapy (CGT) revenue, which rose 26% to $9.1 million. Life Sciences Services and Products segments also grew, supporting 766 global clinical trials and 21 approved CGTs. The company raised its full-year revenue guidance to $192-$196 million, citing ongoing expansion and new supply chain centers opening in Paris and California later this year. This positions Cryoport for continued growth in the life sciences temperature-controlled supply chain market.
The global Edge AI software market is projected to grow from $2.40 billion in 2025 to $8.89 billion by 2031, at a CAGR of 24.4%. This growth is fueled by rising demand for real-time AI decision-making, localized data processing, and intelligent edge ...
Leon Aryah Lewis, a Los Angeles-based mystic, has published his debut book "Inside Out: A Journey of the Soul," which he wrote three decades ago but only recently released. The book blends memoir and spiritual reflections, exploring themes like reinc...
A director at Flywire has sold 6,524 shares of the company's stock, totaling approximately $92,000. This insider sale may indicate personal financial decisions or a shift in confidence, which investors often watch closely. While not necessarily a sig...
Elevance Health reported mixed second-quarter results with adjusted EPS of $7.45 beating estimates, but down 15.7% year-over-year, and a 1.5% decline in medical membership. Operating revenues grew slightly to $49.8 billion, driven by its CarelonRx di...
Teradata is expanding into AI with its new Autonomous Knowledge Platform, prompting RBC Capital to raise its price target to $34 while maintaining a neutral "Sector Perform" rating. Despite optimism about growth in enterprise AI, the stock appears ov...
